The synthesis and antibacterial activity of (7S)-7-(5-aryl-1,3,4-thiadiazol-2-yl-thio)-7-deoxylincomycin derivatives are described. These derivatives were mainly prepared by the Mitsunobu reaction of 2,3,4-tris-O-(trimethylsilyl)lincomycin and the corresponding thiols. Exploring structure-activity relationships of the substituent at the 5 position of a thiadiazole ring revealed that compounds with the ortho substituted phenyl group showed improved antibacterial activities against Streptococcus pneumoniae and Streptococcus pyogenes with erm gene compared with the reported compound (1) that had an unsubstituted benzene ring.
INTRODUCTION
Lincomycin 1 is a secondary metabolite of Streptomyces lincolnensis and active mainly against Gram positive bacteria. Clindamycin 2 (CLDM) derived from lincomycin is a useful semisynthetic antibiotic that is most widely used in the lincosamide class ( Figure 1 ). Lincosamide antibiotics are protein synthesis inhibitors 3 that act on 50S ribosome in a similar way to macrolide antibiotics such as clarithromycin. 4 However, CLDM shows almost no antibacterial activity against resistant pathogens such as Streptococcus pneumoniae and Streptococcus pyogenes with erm gene as shown in Table 1 . Moreover, major macrolides, clarithromycin and azithromycin, 5 are also not active against those pathogens with erm gene. Erm methyltransferases methylate A2058Ec of rRNA and diminish the affinity of clinically important macrolides, lincosamides and streptogramin B 3 , and this mode of resistance is referred to as MLS resistance. 6 Increased emergence of resistant bacteria has been causing serious problems at clinical sites. 7 CLDM is attractive because of its safety and effectiveness against resistant pathogens with efflux pump. It is known that the antibacterial activities of macrolide antibiotics are influenced by efflux pumps of resistant S. pneumoniae and S. pyogenes with mef gene (Figure 1 ; Table 1 ). Furthermore, CLDM can be administered as oral and injectable agents. As a rare case, moreover, it has been reported that CLDM is effective for invasive group A streptococcal infections caused by S. pyogenes. 8 According to these reasons, we selected lincosamide (not macrolide) as a starting material for medicinal chemistry. In order to generate a novel chemotherapeutic agent that is effective against resistant S. pneumoniae and S. pyogenes with erm and mef genes, we started chemical modification of lincomycin and clarified that (7S)-7-arylthio-7-deoxylincomycin derivatives [9] [10] [11] and (7S)-7-(azetidin-3-yl-thio)-7-deoxylincomycin derivatives 12 exhibited moderate to strong antibacterial activities against S. pneumoniae and S. pyogenes with erm gene. In this article, we report optimization of previously reported (7S)-7-deoxy-7-(5-phenyl-1,3,4-thiadiazol-2-yl-thio)lincomycin (1) . On the other hand, telithromycin 13 is effective enough against S. pneumoniae with erm gene, but it has been reported to have potential to cause side effects in clinical use. 7 Novel azalides 14 were generated starting from 16-membered macrolides, and several optimized 16-membered azalides 15 are effective against resistant S. pneumoniae and S. pyogenes with erm gene. These analogs, however, are still under research process and have not been developed yet. Currently available oral drugs are not effective enough against resistant bacteria with erm and mef genes causing respiratory infections and have some problems in safety or taste in clinical site.
Chemistry Schemes 1 and 2 show the synthetic routes for novel (7S)-7-(5-aryl-1,3,4-thiadiazol-2-yl-thio)-7-deoxylincomycin derivatives. We utilized reported 2, 3, 4-tris-O-(trimethylsilyl)lincomycin (2) 16 as a substrate for the Mitsunobu reaction with various thiols as we reported earlier. 10 After the Mitsunobu reaction, trimethylsilyl groups were removed by acid treatment to give 3-22 (Scheme 1). Although [10] [11] [12] in a basic condition to give 24 after an acid treatment (Scheme 2). Compounds 27 and 28 were synthesized by an S N Ar reaction of (7S)-7-deoxy-7-mercaptolincomyicn (25) 11 and methyl 2-(5-chloro-1,3,4-thiadiazol-2-yl)benzoate followed by hydrolysis of methyl ester (26) and condensation of the corresponding amines. A nitro group of compounds 9, 10 and 11 were converted to an amino group by stannous chloride and sodium borohydride to give compounds 29, 30 and 31, respectively.
RESULTS AND DISCUSSION
We reported that compound 1 exhibited weak antibacterial activities against S. pneumoniae and S. pyogenes with erm gene, although CLDM did not show any activities against those pathogens. 10 To enhance the antibacterial activities of compound 1, we first changed the benzene ring of compound 1 to other aryl and hetero aryl groups as shown in Table 2 . Compound 3 having a 2-naphtyl group showed weak antibacterial activities against most of tested pathogens probably due to bulkiness of the substituent based on our three-dimensional analysis. 11 As for pyridine analogs, antibacterial activities of compounds 4 and 5 against erm-resistant S. pneumoniae were comparable to those of compound 1, but compound 6 having a 4-pyridyl group showed decreased activities against those pathogens. Compounds 7 and 8 possessing a thienyl group or a furanyl group showed comparable antibacterial activities against S. pneumoniae to compound 1, but decreased activities against S. pyogenes with erm gene. On the basis of the results obtained in the above, we performed further optimization focusing on substituents on the benzene ring.
To determine the optimal site of a substituent on the phenyl group, we investigated compounds having a nitro group or an amino group as shown in Table 3 . As a matter of fact, compounds having a nitro or an amino group at the ortho position (compounds 9 and 29) exhibited clearly enhanced antibacterial activities against S. pneumoniae with erm gene. Similarly, compounds with those groups at the meta position improved the activities (compounds 10 and 30) but the enhancement effect of the meta substitution seemed to be less than that of the ortho substitution. Antibacterial activities of compounds with a para substituted phenyl group were comparable to those of compound 1 against S. pneumoniae with erm gene but stronger than those of compound 1 against S. pneumoniae with mef gene. On the other hand, the position of a substituent did not significantly affect antibacterial activities against S. pyogenes.
Our finding concerning the ortho substitution at the benzene ring encouraged us to replace the benzene ring with other hetero aromatic rings. Antibacterial activities of compounds having a pyrazole, a pyridine or a pyrazine ring with a nitro or an amino group are shown in Table 4 . Although compound 14 showed improved antibacterial activities against S. pneumoniae with erm gene, its antibacterial activities were limited.
We finally examined other substituents on the benzene ring instead of a nitro or an amino group as shown in Table 5 . Compounds 16, 18 and 19 have an electron donating group at the ortho position of the benzene ring. Among them, compound 16 exhibited comparable antibacterial activities to compounds 9 and 29 against S. pneumoniae and S. pyogenes with erm gene. Among the compounds with an electron withdrawing group, compounds 27 and 22 showed comparable antibacterial activities against S. pneumoniae and S. pyogenes with erm gene to compounds 9 and 29.
CONCLUSIONS
In summary, we identified compounds 9, 16, 22, 27 and 29, which exhibited improved antibacterial activities against S. pneumoniae and S. pyogenes with erm gene by chemical modification of (7S)-7-deoxy-7-(5-phenyl-1,3,4-thiadiazol-2-yl-thio)lincomycin (1). These results indicate that a (7S)-7-deoxy-7-[5-(ortho-substituted-phenyl)-1,3,4-thiadiazol-2-yl-thio]lincomycin analog is a promising framework to overcome resistant S. pneumoniae and S. pyogenes. Further structural optimizations are in progress.
EXPERIMENTAL PROCEDURE General
1 H nuclear magnetic resonance (NMR) spectra were measured with Varian Gemini-300 (Varian, Palo Alto, CA, USA) for 300 MHz, JEOL JNM-GSX 400 (JEOL, Tokyo, Japan) for 400 MHz or BRUKER Ascend 400 NMR spectrometer (BRUKER Corporation, Coventry, UK) for 400 MHz in CDCl 3 or CD 3 OD with 0.03% tetramethylsilane as an internal standard. 13 C NMR spectra were measured with BRUKER Ascend 400 NMR spectrometer (BRUKER Corporation) for 100 MHz. Mass spectra were obtained on a JEOL JMS-FABmate spectrometer or JEOL JMS-700 mass spectrometer or Agilent Technologies 6530-Q-TOF LC/MS mass spectrometer (Agilent Technologies, Santa Clara, CA, USA). The optical rotations were recorded with Jasco P-2300 digital polarimeter (Jasco, Tokyo, Japan). The melting points were measured with Yanaco MP-S (Yanaco, Tokyo, Japan). The infrared (IR) spectra were measured with Jasco FT/IR-410 (Jasco, Tokyo, Japan). Column chromatography was performed with silica gel 60N (Kanto Chemical, Tokyo, Japan; spherical, neutral).
To a solution of compound 2 (240 mg, 0.39 mmol) in tetrahydrofuran (5 ml) at 0°C were added triphenylphosphine (160 mg, 0.61 mmol) and diethylazodicarboxylate (0.1 ml, 0.55 mmol) and stirred at 0°C for 30 min, and 5-(naphthalen-2-yl)-1,3,4-thiadiazole-2-thiol (130 mg, 0.53 mmol) was added and stirred overnight at room temperature. The mixture was concentrated in vacuo and added MeOH (5 ml), 1 N HCl (0.5 ml) and stirred at room temperature for 30 min and concentrated in vacuo. The resulting residue was dissolved in water and washed with diethyl ether. To the mixture was added NaHCO 3 , and the mixture was extracted with ethyl acetate. The organic phase was washed with water, dried over MgSO 4 , filtered and concentrated in vacuo. The resulting residue was purified by preparative thin-layer chromatography (CHCl 3 /CH 3 OH/28% aq NH 4 
(7S)-7-Deoxy-7-[5-(2-nitrophenyl)-1,3,4-thiadiazol-2-ylthio] lincomycin (9)
Reaction of 2 (320 mg, 0.51 mmol) with 5-(2-nitrophenyl)-1,3,4-thiadiazole-2-thiol (160 mg, 0.67 mmol) gave 9 as a colorless solid in 54% yield by a similar in N,N-dimethylformamide (DMF) (2.0 ml) was added 5-(2-aminopyridin-3-yl)-1,3,4-thiadiazole-2-thiol (120 mg, 0.57 mmol) and the mixture was stirred at 80°C for 10 h. After cooled to room temperature, the mixture was diluted with ethyl acetate and washed with brine. The organic phase was dried over Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to give a colorless solid (54 mg). To a solution of the compound obtained above (54 mg) in MeOH (1 ml) was added 1 N HCl (1 ml) and the reaction mixture was stirred at room temperature for 10 min. The mixture was diluted with ethyl acetate and extracted with H 2 O. The aqueous phase was neutralized with 10% aqueous NaHCO 3 and extracted with ethyl acetate. The organic phase was dried over Na 2 SO 4 , filtered and concentrated in vacuo. The resulting residue was purified by preparative thin-layer chromatography (CHCl 3 /CH 3 OH/28% aq NH 4 To a solution of 25 11 (80 mg, 0.19 mmol) in DMF (0.5 ml) were added 1 M sodium hexamethyldisilazane tetrahydrofuran solution (0.38 ml, 0.38 mmol) and methyl 2-(5-chloro-1,3,4-thiadiazol-2-yl)benzoate (53 mg, 0.21 mmol) and the mixture was stirred at room temperature for 10 min. The mixture was diluted with ethyl acetate and washed with water. The organic phase was dried over Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (CHCl 3 -MeOH) to give a colorless solid (93 mg). 1 
